DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia.

ABSTRACT:

Background

DNA methylation markers are considered robust diagnostic features in various cancer types, as epigenetic marks are commonly altered during cancer progression. Differentiation between benign prostatic hyperplasia (BPH) and early-stage prostate cancer (PCa) is clinically difficult, relying on the information of the patient's symptoms or levels of prostate-specific antigen.

Methods

A total of 42 PCa patients and 11 BPH patients were recruited. Genomic DNA was purified from tissues and used for the library preparation of the target-enriched methylome with enzymatic conversion and a Twist 85 Mbp EM-seq panel. Paired-end sequencing (150 bp) was performed using NovaSeq 6000 or NextSeq 550. After quality control, including adapter trimming and de-duplication of raw sequen

SUBMITTER: Kim SS 

PROVIDER: S-EPMC10318333 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature